A single-domain antibody library based on a stability-engineered human VH3 scaffold.
Nanobody
Phage display
Single-domain antibody
Stable scaffold
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
received:
14
05
2024
accepted:
25
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Using conventional immunoglobulin G (IgG) molecules as therapeutic agents presents several well-known disadvantages owing to their large size and structural complexity, negatively impacting development and production efficiency. Single-domain antibodies (sdAbs) are the smallest functional antibody format (~ 15 kDa) and represent a viable alternative to IgG in many applications. However, unlike natural single-domain antibodies, such as camelid V
Identifiants
pubmed: 39085444
doi: 10.1038/s41598-024-68680-5
pii: 10.1038/s41598-024-68680-5
doi:
Substances chimiques
Single-Domain Antibodies
0
Peptide Library
0
Complementarity Determining Regions
0
Immunoglobulin Heavy Chains
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17747Subventions
Organisme : National Research Foundation of Korea
ID : 2021R1A6A10039823
Organisme : Korea Drug Development Fund
ID : RS-2021-DD116299
Organisme : Ministry of Education
ID : 2019R1A6C1010020
Informations de copyright
© 2024. The Author(s).
Références
Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361–370. https://doi.org/10.1038/nrc3930 (2015).
doi: 10.1038/nrc3930
pubmed: 25998715
pmcid: 4491443
Fernandes, J. C. Therapeutic application of antibody fragments in autoimmune diseases: Current state and prospects. Drug Discov. Today 23, 1996–2002. https://doi.org/10.1016/j.drudis.2018.06.003 (2018).
doi: 10.1016/j.drudis.2018.06.003
pubmed: 29890227
Kholodenko, R. V., Kalinovsky, D. V., Doronin, I. I., Ponomarev, E. D. & Kholodenko, I. V. Antibody fragments as potential biopharmaceuticals for cancer therapy: Success and limitations. Curr. Med. Chem. 26, 396–426. https://doi.org/10.2174/0929867324666170817152554 (2019).
doi: 10.2174/0929867324666170817152554
pubmed: 28820071
Andersen, D. C. & Reilly, D. E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 15, 456–462. https://doi.org/10.1016/j.copbio.2004.08.002 (2004).
doi: 10.1016/j.copbio.2004.08.002
pubmed: 15464378
Almagro, J. C., Pedraza-Escalona, M., Arrieta, H. I. & Perez-Tapia, S. M. Phage display libraries for antibody therapeutic discovery and development. Antibodies (Basel) https://doi.org/10.3390/antib8030044 (2019).
doi: 10.3390/antib8030044
pubmed: 31544850
Nagano, K. & Tsutsumi, Y. Phage display technology as a powerful platform for antibody drug discovery. Viruses https://doi.org/10.3390/v13020178 (2021).
doi: 10.3390/v13020178
pubmed: 33504115
pmcid: 7912188
Shim, H. Therapeutic antibodies by phage display. Curr. Pharm. Des. 22, 6538–6559. https://doi.org/10.2174/1381612822666160923113714 (2016).
doi: 10.2174/1381612822666160923113714
pubmed: 27669967
Adams, J. J. & Sidhu, S. S. Synthetic antibody technologies. Curr. Opin. Struct. Biol. 24, 1–9. https://doi.org/10.1016/j.sbi.2013.11.003 (2014).
doi: 10.1016/j.sbi.2013.11.003
pubmed: 24721448
Finlay, W. J. & Almagro, J. C. Natural and man-made V-gene repertoires for antibody discovery. Front. Immunol. 3, 342. https://doi.org/10.3389/fimmu.2012.00342 (2012).
doi: 10.3389/fimmu.2012.00342
pubmed: 23162556
pmcid: 3498902
Shim, H. Synthetic approach to the generation of antibody diversity. BMB Rep. 48, 489–494. https://doi.org/10.5483/bmbrep.2015.48.9.120 (2015).
doi: 10.5483/bmbrep.2015.48.9.120
pubmed: 26129672
pmcid: 4641231
Dudgeon, K. et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc. Natl. Acad. Sci. U. S. A. 109, 10879–10884. https://doi.org/10.1073/pnas.1202866109 (2012).
doi: 10.1073/pnas.1202866109
pubmed: 22745168
pmcid: 3390889
Dooley, H., Grant, S. D., Harris, W. J. & Porter, A. J. Stabilization of antibody fragments in adverse environments. Biotechnol. Appl. Biochem. 28, 77–83. https://doi.org/10.1111/j.1470-8744.1998.tb00515.x (1998).
doi: 10.1111/j.1470-8744.1998.tb00515.x
pubmed: 9693092
Ewert, S., Huber, T., Honegger, A. & Pluckthun, A. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325, 531–553. https://doi.org/10.1016/s0022-2836(02)01237-8 (2003).
doi: 10.1016/s0022-2836(02)01237-8
pubmed: 12498801
Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446–448. https://doi.org/10.1038/363446a0 (1993).
doi: 10.1038/363446a0
pubmed: 8502296
Harmsen, M. M. & De Haard, H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13–22. https://doi.org/10.1007/s00253-007-1142-2 (2007).
doi: 10.1007/s00253-007-1142-2
pubmed: 17704915
pmcid: 2039825
Riechmann, L. & Muyldermans, S. Single domain antibodies: Comparison of camel VH and camelised human VH domains. J. Immunol. Methods 231, 25–38. https://doi.org/10.1016/s0022-1759(99)00138-6 (1999).
doi: 10.1016/s0022-1759(99)00138-6
pubmed: 10648925
Barthelemy, P. A. et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283, 3639–3654. https://doi.org/10.1074/jbc.M708536200 (2008).
doi: 10.1074/jbc.M708536200
pubmed: 18045863
Rouet, R., Dudgeon, K., Christie, M., Langley, D. & Christ, D. Fully Human VH single domains that rival the stability and cleft recognition of camelid antibodies. J. Biol. Chem. 290, 11905–11917. https://doi.org/10.1074/jbc.M114.614842 (2015).
doi: 10.1074/jbc.M114.614842
pubmed: 25737448
pmcid: 4424330
Belanger, K. & Tanha, J. High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources. Protein Eng. Des. Sel. https://doi.org/10.1093/protein/gzab012 (2021).
doi: 10.1093/protein/gzab012
pubmed: 33991089
To, R. et al. Isolation of monomeric human V(H)s by a phage selection. J. Biol. Chem. 280, 41395–41403. https://doi.org/10.1074/jbc.M509900200 (2005).
doi: 10.1074/jbc.M509900200
pubmed: 16221664
Henry, K. A. et al. Stability-diversity tradeoffs impose fundamental constraints on selection of synthetic human V(H)/V(L) single-domain antibodies from in vitro display libraries. Front. Immunol. 8, 1759. https://doi.org/10.3389/fimmu.2017.01759 (2017).
doi: 10.3389/fimmu.2017.01759
pubmed: 29375542
pmcid: 5763143
Mandrup, O. A., Friis, N. A., Lykkemark, S., Just, J. & Kristensen, P. A novel heavy domain antibody library with functionally optimized complementarity determining regions. PLoS One 8, e76834. https://doi.org/10.1371/journal.pone.0076834 (2013).
doi: 10.1371/journal.pone.0076834
pubmed: 24116173
pmcid: 3792991
Saerens, D. et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 352, 597–607. https://doi.org/10.1016/j.jmb.2005.07.038 (2005).
doi: 10.1016/j.jmb.2005.07.038
pubmed: 16095608
Murakami, T. et al. Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics. Antibodies (Basel) https://doi.org/10.3390/antib11010010 (2022).
doi: 10.3390/antib11010010
pubmed: 35225868
pmcid: 8835874
Nguyen, V. K., Su, C., Muyldermans, S. & van der Loo, W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics 54, 39–47. https://doi.org/10.1007/s00251-002-0433-0 (2002).
doi: 10.1007/s00251-002-0433-0
pubmed: 11976790
Potter, K. N., Li, Y. & Capra, J. D. Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs. J. Immunol. 157, 2982–2988. https://doi.org/10.4049/jimmunol.157.7.2982 (1996).
doi: 10.4049/jimmunol.157.7.2982
pubmed: 8816406
Wang, T. & Duan, Y. Probing the stability-limiting regions of an antibody single-chain variable fragment: A molecular dynamics simulation study. Protein Eng. Des. Sel. 24, 649–657. https://doi.org/10.1093/protein/gzr029 (2011).
doi: 10.1093/protein/gzr029
pubmed: 21729946
pmcid: 3160207
Baral, T. N. et al. Crystal structure of a human single domain antibody dimer formed through V(H)-V(H) non-covalent interactions. PLoS One 7, e30149. https://doi.org/10.1371/journal.pone.0030149 (2012).
doi: 10.1371/journal.pone.0030149
pubmed: 22253912
pmcid: 3257273
Zemlin, M. et al. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J. Mol. Biol. 334, 733–749. https://doi.org/10.1016/j.jmb.2003.10.007 (2003).
doi: 10.1016/j.jmb.2003.10.007
pubmed: 14636599
Chen, L., Duan, Y., Benatuil, L. & Stine, W. B. Analysis of 5518 unique, productively rearranged human VH3-23*01 gene sequences reveals CDR-H3 length-dependent usage of the IGHD2 gene family. Protein Eng. Des. Sel. 30, 603–609. https://doi.org/10.1093/protein/gzx027 (2017).
doi: 10.1093/protein/gzx027
pubmed: 28472386
La Verde, V., Dominici, P. & Astegno, A. Determination of hydrodynamic radius of proteins by size exclusion chromatography. Bio-Protocol 7, e2230. https://doi.org/10.21769/BioProtoc.2230 (2017).
doi: 10.21769/BioProtoc.2230
pubmed: 34541230
pmcid: 8410290
Burgess, R. R. A brief practical review of size exclusion chromatography: Rules of thumb, limitations, and troubleshooting. Protein Expr. Purif. 150, 81–85. https://doi.org/10.1016/j.pep.2018.05.007 (2018).
doi: 10.1016/j.pep.2018.05.007
pubmed: 29777748
Liu, S. et al. Characterization of monoclonal antibody’s binding kinetics using oblique-incidence reflectivity difference approach. MAbs 7, 110–119. https://doi.org/10.4161/19420862.2014.985919 (2015).
doi: 10.4161/19420862.2014.985919
pubmed: 25530170
Valdes-Tresanco, M. S., Valdes-Tresanco, M. E., Molina-Abad, E. & Moreno, E. NbThermo: A new thermostability database for nanobodies. Database (Oxford) https://doi.org/10.1093/database/baad021 (2023).
doi: 10.1093/database/baad021
pubmed: 37042467
Jespers, L., Schon, O., James, L. C., Veprintsev, D. & Winter, G. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J. Mol. Biol. 337, 893–903. https://doi.org/10.1016/j.jmb.2004.02.013 (2004).
doi: 10.1016/j.jmb.2004.02.013
pubmed: 15033359
Davies, J. & Riechmann, L. Single antibody domains as small recognition units: Design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. 9, 531–537. https://doi.org/10.1093/protein/9.6.531 (1996).
doi: 10.1093/protein/9.6.531
pubmed: 8862554
Branston, S. D., Stanley, E. C., Ward, J. M. & Keshavarz-Moore, E. Determination of the survival of bacteriophage M13 from chemical and physical challenges to assist in its sustainable bioprocessing. Biotechnol. Bioprocess E 18, 560–566. https://doi.org/10.1007/s12257-012-0776-9 (2013).
doi: 10.1007/s12257-012-0776-9
Jespers, L., Schon, O., Famm, K. & Winter, G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 22, 1161–1165. https://doi.org/10.1038/nbt1000 (2004).
doi: 10.1038/nbt1000
pubmed: 15300256
Dudgeon, K., Rouet, R., Famm, K. & Christ, D. Selection of human VH single domains with improved biophysical properties by phage display. Methods Mol. Biol. 911, 383–397. https://doi.org/10.1007/978-1-61779-968-6_23 (2012).
doi: 10.1007/978-1-61779-968-6_23
pubmed: 22886264
Kim, D. Y. et al. Antibody light chain variable domains and their biophysically improved versions for human immunotherapy. MAbs 6, 219–235. https://doi.org/10.4161/mabs.26844 (2014).
doi: 10.4161/mabs.26844
pubmed: 24423624
Dubnovitsky, A. P. et al. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc) 65, 1011–1018 (2000).
pubmed: 11042491
Hussack, G. et al. A V(L) single-domain antibody library shows a high-propensity to yield non-aggregating binders. Protein Eng. Des. Sel. 25, 313–318. https://doi.org/10.1093/protein/gzs014 (2012).
doi: 10.1093/protein/gzs014
pubmed: 22490957
Knappik, A. et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296, 57–86. https://doi.org/10.1006/jmbi.1999.3444 (2000).
doi: 10.1006/jmbi.1999.3444
pubmed: 10656818
Wu, T. T. & Kabat, E. A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132, 211–250. https://doi.org/10.1084/jem.132.2.211 (1970).
doi: 10.1084/jem.132.2.211
pubmed: 5508247
pmcid: 2138737
Prabakaran, P. & Chowdhury, P. S. Landscape of non-canonical cysteines in human V(H) repertoire revealed by immunogenetic analysis. Cell Rep. 31, 107831. https://doi.org/10.1016/j.celrep.2020.107831 (2020).
doi: 10.1016/j.celrep.2020.107831
pubmed: 32610132
pmcid: 7326410
Zavrtanik, U., Lukan, J., Loris, R., Lah, J. & Hadzi, S. Structural basis of epitope recognition by heavy-chain camelid antibodies. J. Mol. Biol. 430, 4369–4386. https://doi.org/10.1016/j.jmb.2018.09.002 (2018).
doi: 10.1016/j.jmb.2018.09.002
pubmed: 30205092
Muyldermans, S. Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797. https://doi.org/10.1146/annurev-biochem-063011-092449 (2013).
doi: 10.1146/annurev-biochem-063011-092449
pubmed: 23495938
Hu, X. et al. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J. Nanobiotechnol. 20, 237. https://doi.org/10.1186/s12951-022-01456-z (2022).
doi: 10.1186/s12951-022-01456-z
Jiang, X., Qin, Q., Zhu, H., Qian, J. & Huang, Q. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein. Int. J. Biol. Macromol. 256, 128191. https://doi.org/10.1016/j.ijbiomac.2023.128191 (2024).
doi: 10.1016/j.ijbiomac.2023.128191
pubmed: 38000614
Ahmad, J. et al. Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. J. Biol. Chem. 297, 101202. https://doi.org/10.1016/j.jbc.2021.101202 (2021).
doi: 10.1016/j.jbc.2021.101202
pubmed: 34537245
pmcid: 8444450
Manivel, V., Sahoo, N. C., Salunke, D. M. & Rao, K. V. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13, 611–620. https://doi.org/10.1016/s1074-7613(00)00061-3 (2000).
doi: 10.1016/s1074-7613(00)00061-3
pubmed: 11114374
Thorpe, I. F. & Brooks, C. L. 3rd. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. U. S. A. 104, 8821–8826. https://doi.org/10.1073/pnas.0610064104 (2007).
doi: 10.1073/pnas.0610064104
pubmed: 17488816
pmcid: 1885586
Li, T. et al. Rigidity emerges during antibody evolution in three distinct antibody systems: Evidence from QSFR analysis of fab fragments. PLoS Comput. Biol. 11, e1004327. https://doi.org/10.1371/journal.pcbi.1004327 (2015).
doi: 10.1371/journal.pcbi.1004327
pubmed: 26132144
pmcid: 4489365
Yang, H. Y., Kang, K. J., Chung, J. E. & Shim, H. Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol. Cells 27, 225–235. https://doi.org/10.1007/s10059-009-0028-9 (2009).
doi: 10.1007/s10059-009-0028-9
pubmed: 19277506
Scott, J. K. & Barbas III, C. F. in Phage Display: A Laboratory Manual (eds Barbas III, C. F., Burton, D. R., Scott, J. K., & Silverman, G. J.) (Cold Spring Harbor Laboratory Press, 2001).